First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

During a live event, Pedro C. Barata, MD, MSc, discussed the case of a patient with advanced clear cell renal cell carcinoma ...

Melphalan/hepatic delivery system showed better survival and response rates than best alternative care in metastatic uveal ...

CytomX Therapeutics, Inc.’s CTMX share price has dipped by 9.45%, which has investors questioning if this is right time to ...

Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

Specifically, Opdivo Qvantig is prescribed to treat: Note: Opdivo Qvantig is not approved for use in combination with ipilimumab (Yervoy) to treat RCC. Opdivo Qvantig is prescribed to treat ...

Immuno-oncology pioneer partners with AbTherx to build the next generation of immunotherapy drugs MOUNTAIN VIEW, CA / ACCESS Newswire / May 12, 2025 / AbTherx, Inc., a biotechnology company with ...

Here this group reports a phase 2 NIMBUS trial evaluating the efficacy/safety of nivolumab + low dose ipilimumab in 30 patients with hypermutated HER2-negative MBC. Interpreting bone metastases ...